Drug Trial Radar · NCT07276282
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Sep 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- ECRI bvIndustry
- Sponsor type
- Industry
- Collaborators
- Novo Nordisk A/S; Insel Gruppe AG, University Hospital Bern; Cardialysis B.V.
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized again within a year, and 10% experience another heart attack. Despite currently available medication, patients remain at risk of further episodes after a heart attack. Scientists have discovered that inflammation in the body plays a decisive role in the development and narrowing of arterial blockages (atherosclerosis). This study aims to investigate whether a new treatment that reduces inflammation can help improve the arteries of patients with CAD. This study will examine whether blocking certain inflammation-related substances with a new medicinal product called ziltivekimab affects the buildup and composition of plaques (fatty deposits) in the coronary arteries. Special imaging diagnostic techniques will be used to look inside the arteries and check whether the treatment helps reduce the narrowing caused by dangerous plaques, which can lead to future heart attacks. This is a clinical study in which participants are randomly divided into two groups (randomization): one group will receive the new treatment ziltivekimab and other group will receive a placebo (a harmless substance with no active ingredients). Both groups will continue to receive standard treatment for heart attacks. The study lasts approximately 15 months per participant. The full scientific title of the trial is: Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A study with serial multi-vessel imaging obtained using intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography techniques.
Conditions
- Coronary Artery Disease
- Acute Myocardial Infarction (AMI)
- Coronary Atherosclerosis of Native Coronary Artery
Interventions
ZiltivekimabDrug
Ziltivekimab is administered subcutaneously (i.e., under the skin) once per month added to standard of care.
PlaceboDrug
Placebo is administered subcutaneously (i.e., under the skin) once per month added to standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in percent atheroma volumeTime frame: From randomization (week 0) to end-of-study (52-week)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bern University Hospital, Inselspital Bern
Bern, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.